393 related articles for article (PubMed ID: 15627919)
21. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients.
Resmini E; Barreca A; Ferone D; Giusti M; Sidoti M; Minuto F
Clin Endocrinol (Oxf); 2005 Sep; 63(3):294-7. PubMed ID: 16117816
[TBL] [Abstract][Full Text] [Related]
22. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
23. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
Kreutzer J; Vance ML; Lopes MB; Laws ER
J Clin Endocrinol Metab; 2001 Sep; 86(9):4072-7. PubMed ID: 11549628
[TBL] [Abstract][Full Text] [Related]
24. Acromegaly: presentation, morbidity and treatment outcomes at a single centre.
Anagnostis P; Efstathiadou ZA; Polyzos SA; Adamidou F; Slavakis A; Sapranidis M; Litsas ID; Katergari S; Selalmatzidou D; Kita M
Int J Clin Pract; 2011 Aug; 65(8):896-902. PubMed ID: 21679284
[TBL] [Abstract][Full Text] [Related]
25. Improvement in remission rates of the first operation in acromegalic patients.
Demir O; Gedik V; Corapcioglu D; Emral R; Unlu MA; Erdogan MF; Gullu S; Uysal AR; Baskal N
Turk Neurosurg; 2012; 22(5):645-50. PubMed ID: 23015345
[TBL] [Abstract][Full Text] [Related]
26. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of the efficacy of Octreotide LAR in the treatment of acromegaly--a yearly observation].
Bałdys-Waligórska A; Gołkowski F; Krzentowska A; Sokołowski G; Hubalewska-Dydejczyk A
Przegl Lek; 2009; 66(5):218-21. PubMed ID: 19739577
[TBL] [Abstract][Full Text] [Related]
28. The use of neuronavigation in transnasal transsphenoidal pituitary surgery.
Thomale UW; Stover JF; Unterberg AW
Zentralbl Neurochir; 2005 Aug; 66(3):126-32; discussion 132. PubMed ID: 16116555
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.
Taweesomboonyat C; Oearsakul T
World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643
[TBL] [Abstract][Full Text] [Related]
30. [The treatment of acromegaly].
Beauregard H; Somma M; Rasio E; Serri O; Aris-Jilwan N; Comtois R; Long H; Abribat T; Boucher A; Hardy J
Union Med Can; 1993; 122(6):489-95. PubMed ID: 8303792
[TBL] [Abstract][Full Text] [Related]
31. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status.
Espinosa-de-Los-Monteros AL; Sosa E; Cheng S; Ochoa R; Sandoval C; Guinto G; Mendoza V; Hernández I; Molina M; Mercado M
Clin Endocrinol (Oxf); 2006 Mar; 64(3):245-9. PubMed ID: 16487431
[TBL] [Abstract][Full Text] [Related]
32. Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients.
Minniti G; Jaffrain-Rea ML; Esposito V; Santoro A; Moroni C; Lenzi J; Tamburrano G; Cassone R; Cantore G
Acta Neurochir (Wien); 2001 Dec; 143(12):1205-11. PubMed ID: 11810383
[TBL] [Abstract][Full Text] [Related]
33. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'.
Nomikos P; Buchfelder M; Fahlbusch R
Eur J Endocrinol; 2005 Mar; 152(3):379-87. PubMed ID: 15757854
[TBL] [Abstract][Full Text] [Related]
34. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.
De P; Rees DA; Davies N; John R; Neal J; Mills RG; Vafidis J; Davies JS; Scanlon MF
J Clin Endocrinol Metab; 2003 Aug; 88(8):3567-72. PubMed ID: 12915637
[TBL] [Abstract][Full Text] [Related]
35. A follow-up of 130 patients with acromegaly in a single centre.
Bolanowski M; Zatonska K; Kaluzny M; Zielinski G; Bednarek-Tupikowska G; Bohdanowicz-Pawlak A; Daroszewski J; Szymczak J; Podgorski JK
Neuro Endocrinol Lett; 2006 Dec; 27(6):828-32. PubMed ID: 17187024
[TBL] [Abstract][Full Text] [Related]
36. Repeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing's disease (CD).
Wagenmakers MA; Netea-Maier RT; van Lindert EJ; Timmers HJ; Grotenhuis JA; Hermus AR
Clin Endocrinol (Oxf); 2009 Feb; 70(2):274-80. PubMed ID: 18616702
[TBL] [Abstract][Full Text] [Related]
37. Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results.
Santoro A; Minniti G; Ruggeri A; Esposito V; Jaffrain-Rea ML; Delfini R
Surg Neurol; 2007 Nov; 68(5):513-8; discussion 518. PubMed ID: 17961741
[TBL] [Abstract][Full Text] [Related]
38. Therapy for the syndromes of GH excess.
Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
[TBL] [Abstract][Full Text] [Related]
39. Fully endoscopic transsphenoidal surgery for functioning pituitary adenomas: a retrospective comparison with traditional transsphenoidal microsurgery in the same institution.
D'Haens J; Van Rompaey K; Stadnik T; Haentjens P; Poppe K; Velkeniers B
Surg Neurol; 2009 Oct; 72(4):336-40. PubMed ID: 19604551
[TBL] [Abstract][Full Text] [Related]
40. Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients.
Esposito V; Santoro A; Minniti G; Salvati M; Innocenzi G; Lanzetta G; Cantore G
Neurol Sci; 2004 Dec; 25(5):251-6. PubMed ID: 15624082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
